Austin-based MDisrupt, an AI-powered healthcare technology marketplace, has secured a $1 million milestone-based investment from American Heart Association (AHA) Ventures.
The newly formed venture from AHA is designed to lead AHA’s investments and support breakthrough innovation that aligns with the organization’s mission.
In parallel with this funding, MDisrupt and AHA entered into a services agreement to co-develop a platform that connects healthcare professionals and innovators. This expansion will leverage AHA’s vast network of clinicians, scientists, and business experts. By integrating these resources into MDisrupt’s marketplace, this partnership aims to bridge the gap between innovation and clinical expertise.
Founded by Ruby Gadelrab, MDisrupt provides an AI-powered matching platform that pairs healthcare and medtech companies with industry experts with over 10 years of experience. This setting allows companies to access expert guidance in building clinically sound and impactful products. “We handle all contracts, liability insurance and logistics, allowing clinicians and medical professionals to focus on advising rather than managing industry operations,” Gadellove said in a news release.
This new collaboration with AHA Ventures brings the expertise of AHA members to MDisrupt’s platform. Lisa Suenen, Managing Partner at AHA Ventures, explained: MDisrupt’s commitment to evidence-based matchmaking aligns with our goals. ”
Suenen noted that AHA’s investment structure reflects AHA’s commitment to ensuring the platform’s development, with “three-quarters of the funding provided upfront and the remaining one-quarter jointly.” It all depends on the successful launch of the beta version of the developed product.” Scheduled for a beta release in late 2025, the platform aims to facilitate referrals to experts and enable innovators to apply science-backed insights across development.
For MDisrupt, this partnership is an opportunity to expand the role of expert opinion in health technology. “Our mission is to help bring the most impactful healthcare products to market faster by providing the right regulatory, clinical, and operational insights to help them become truly viable. to support,” Gadellove said.
With this collaborative development platform between MDisrupt and AHA Ventures, both parties expect to have a significant impact on the quality and clinical relevance of next-generation healthcare and medical technology solutions. Suenen concluded, “Our hope is that MDisrupt’s growth and success will bring in more trust and partners to further raise the standards of medical technology.”
